Denali Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

DNLI$20.33+1.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

	March 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$56,947	$174,960
Short-term marketable securities	760,979	657,371
Prepaid expenses and other current assets	60,712	32,105
Total current assets	878,638	864,436
Long-term marketable securities	235,844	359,373
Property and equipment, net	57,765	55,236
Finance lease right-of-use asset	50,199	47,533
Operating lease right-of-use asset	21,963	22,861
Other non-current assets	26,934	24,741
Total assets	$1,271,343	$1,374,180
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$8,458	$11,137
Accrued compensation	7,655	24,728
Accrued clinical and other research and development costs	27,908	22,822
Accrued manufacturing costs	14,579	12,779
Operating lease liability, current	8,585	8,308
Deferred research and development funding liability, current	17,338	14,129
Other accrued costs and current liabilities	7,354	8,305
Total current liabilities	91,877	102,208
Operating lease liability, less current portion	34,449	36,673
Finance lease liability, less current portion	5,598	5,615
Deferred research funding and development liability, less current portion	16,733	—
Total liabilities	148,657	144,496
Commitments and contingencies (Note 6)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024	—	—
Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 145,251,258 shares and 144,220,986 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	1,778	1,768
Additional paid-in capital	2,790,825	2,764,880
Accumulated other comprehensive income	2,037	2,020
Accumulated deficit	(1,671,954)	(1,538,984)
Total stockholders' equity	1,122,686	1,229,684
Total liabilities and stockholders’ equity	$1,271,343	$1,374,180

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.